Virax Biolabs Group LimitedNASDAQ: VRAX

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

Virax Biolabs Group Limited is in the Healthcare sector

Virax Biolabs Group Limited is in the Biotechnology industry

Virax Biolabs Group Limited is headquartered in United Kingdom

Virax Biolabs Group Limited initial public offering (IPO) was on 21 July 2022

https://viraxbiolabs.com

No, Virax Biolabs Group Limited is not included in the S&P 500 index

No, Virax Biolabs Group Limited is not included in the NASDAQ 100 index

No, Virax Biolabs Group Limited is not included in the Dow Jones index